Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

Author： Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.6, 2013-12, pp. : 1299-1304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors

By Tsuboi Masahiro   Chevalier Thierry  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 161-170

Humana Press, Inc

Access to resources Recommend Favorite

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients

By Sun Jong-Mu   Won Young-Woong   Kim Seung   Kim Jung   Choi Yoon-La   Lee Jeeyun   Park Yeon   Ahn Jin   Park Keunchil   Ahn Myung-Ju  

Journal of Cancer Research and Clinical Oncology, Vol. 137, Iss. 4, 2011-04 ,pp. : 687-694

Springer Publishing Company

Access to resources Recommend Favorite

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

By Giaccone Giuseppe   Iacona Renee   Fandi Abderrahim   Janas Mette   Ochs Judith   Herbst Roy   Johnson David  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 467-476

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

By Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 993-999

Oxford University Press

Access to resources Recommend Favorite